Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

Tomohiro Ishii, Makoto Anzo, Masanori Adachi, Kazumichi Onigata, Satoshi Kusuda, Keisuke Nagasaki, Shohei Harada, Reiko Horikawa, Masanori Minagawa, Kanshi Minamitani, Haruo Mizuno, Yuji Yamakami, Masaru Fukushi, Toshihiro Tajima

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

Original languageEnglish
Pages (from-to)77-105
Number of pages29
JournalClinical Pediatric Endocrinology
Volume24
Issue number3
Publication statusPublished - 2015 Jul 18

Fingerprint

Guidelines
Pediatrics
Mass Screening
Endocrinology
Physicians
Therapeutics
Neonatal Screening
Congenital Adrenal Hyperplasia
General Practitioners
Japan
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency

Keywords

  • 21-hydroxylase deficiency
  • Guideline
  • Mass screening

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Ishii, T., Anzo, M., Adachi, M., Onigata, K., Kusuda, S., Nagasaki, K., ... Tajima, T. (2015). Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). Clinical Pediatric Endocrinology, 24(3), 77-105.

Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). / Ishii, Tomohiro; Anzo, Makoto; Adachi, Masanori; Onigata, Kazumichi; Kusuda, Satoshi; Nagasaki, Keisuke; Harada, Shohei; Horikawa, Reiko; Minagawa, Masanori; Minamitani, Kanshi; Mizuno, Haruo; Yamakami, Yuji; Fukushi, Masaru; Tajima, Toshihiro.

In: Clinical Pediatric Endocrinology, Vol. 24, No. 3, 18.07.2015, p. 77-105.

Research output: Contribution to journalArticle

Ishii, T, Anzo, M, Adachi, M, Onigata, K, Kusuda, S, Nagasaki, K, Harada, S, Horikawa, R, Minagawa, M, Minamitani, K, Mizuno, H, Yamakami, Y, Fukushi, M & Tajima, T 2015, 'Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)', Clinical Pediatric Endocrinology, vol. 24, no. 3, pp. 77-105.
Ishii T, Anzo M, Adachi M, Onigata K, Kusuda S, Nagasaki K et al. Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). Clinical Pediatric Endocrinology. 2015 Jul 18;24(3):77-105.
Ishii, Tomohiro ; Anzo, Makoto ; Adachi, Masanori ; Onigata, Kazumichi ; Kusuda, Satoshi ; Nagasaki, Keisuke ; Harada, Shohei ; Horikawa, Reiko ; Minagawa, Masanori ; Minamitani, Kanshi ; Mizuno, Haruo ; Yamakami, Yuji ; Fukushi, Masaru ; Tajima, Toshihiro. / Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). In: Clinical Pediatric Endocrinology. 2015 ; Vol. 24, No. 3. pp. 77-105.
@article{f2fd37460365488f8b808e5eaa654049,
title = "Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)",
abstract = "Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.",
keywords = "21-hydroxylase deficiency, Guideline, Mass screening",
author = "Tomohiro Ishii and Makoto Anzo and Masanori Adachi and Kazumichi Onigata and Satoshi Kusuda and Keisuke Nagasaki and Shohei Harada and Reiko Horikawa and Masanori Minagawa and Kanshi Minamitani and Haruo Mizuno and Yuji Yamakami and Masaru Fukushi and Toshihiro Tajima",
year = "2015",
month = "7",
day = "18",
language = "English",
volume = "24",
pages = "77--105",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",
number = "3",

}

TY - JOUR

T1 - Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

AU - Ishii, Tomohiro

AU - Anzo, Makoto

AU - Adachi, Masanori

AU - Onigata, Kazumichi

AU - Kusuda, Satoshi

AU - Nagasaki, Keisuke

AU - Harada, Shohei

AU - Horikawa, Reiko

AU - Minagawa, Masanori

AU - Minamitani, Kanshi

AU - Mizuno, Haruo

AU - Yamakami, Yuji

AU - Fukushi, Masaru

AU - Tajima, Toshihiro

PY - 2015/7/18

Y1 - 2015/7/18

N2 - Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

AB - Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

KW - 21-hydroxylase deficiency

KW - Guideline

KW - Mass screening

UR - http://www.scopus.com/inward/record.url?scp=84937858666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937858666&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 77

EP - 105

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

IS - 3

ER -